Abstract
To develop better analytical approaches for future global pandemics, it is widely recognized that sensing materials are necessary that enable molecular recognition and sensor assay development on a much faster scale than currently possible. Previously developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) point-of-care devices are based on the specific molecular recognition using subunit protein antibodies and protein receptors that selectively capture the viral proteins. However, these necessarily involve complex and lengthy development and processing times, and are notoriously prone to a loss of biological activity upon sensor immobilization and device interfacing, potentially limiting their use in applications at scale. Here, we report a synthetic strategy for nanoparticle corona interfaces that enables the molecular recognition of SARS-CoV-2 proteins without any antibody and receptor design. Our nanosensor constructs consist of polyethylene glycol (PEG) - phospholipid heteropolymers adsorbed onto near infrared (nIR) fluorescent single-walled carbon nanotubes (SWCNT) that recognize the nucleocapsid (N) and spike (S) protein of SARS-CoV-2 using unique three-dimensional (3D) nanosensor interfaces. This results in rapid and label-free nIR fluorescence detection. This antibody-free nanosensor shows up-to 50% sensor responses within 5 min viral protein injections with limit of detection (LOD) of 48 fM and 350 pM for N and S protein, respectively. Finally, we demonstrate instrumentation based on a fiber optic platform that interfaces the advantages of antibody-free molecular recognition and biofluid compatibility in human saliva condition.
Graphical Abstract

Rapid and accurate detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is critical for reducing morbidity of Coronavirus Disease 2019 (COVID-19).1 The current methodology in assessing the present infection of SARS-CoV-2 relies on two analytics: (i) nucleic acid-based tests (NAT) which detect the genetic material (RNA) from SARS-CoV-2 and (ii) serological tests which detect the presence of antibodies (IgG and IgM) against SARS-CoV-2.2 NAT primarily uses reverse-transcription polymerase chain reaction (RT-PCR) to amplify and detect the SARS-CoV-2 RNA in the patient. Since RT-PCR demonstrate superior sensitivity for viral RNA detection with a limit of detection (LOD) of a few viral RNA copies, the NAT is the preferred testing methods to diagnose SARS-CoV-2 positive cases to date.3 However, this method is composed of highly complex processes which requires specialized equipment, trained personnel, and long turnaround time limiting the high-throughput diagnosis of large populations and wide testing accessibility in rural regions.4–6 Serological test, in general, is based on lateral flow immunoassay (LFA) platform, which is relatively easy, inexpensive having a short turnaround time, and amenable to point-of-care diagnostic methodologies.7 However, the sensitivity of antigen test is generally not high enough to accurately screen the positive cases and provide past viral infections data. Thus, it is hard to identify current active cases.7–9 Therefore, there has been a strong drive to find next-generation viral testing technology for faster and simpler diagnostics of large populations, which can directly detect viral antigens in clinical samples without complicated sample preparation steps. In addition, even though NAT and LFA based diagnostics have a lot of advantages, we could not have wide deployment of these test kit until few months of early phase of pandemic due to complicated development process including sensor design, validation, and implementation, and shortages of laboratory item.10,11 Thus, accelerated point-of-care sensor development process should be developed for future viral targets.
Several potentially useful new analytics for rapid and sensitive SARS-CoV-2 detection have emerged for diagnosis of COVID-19 against RT-PCR and serological test, including field-effect transistor (FET) sensing devices,12–14 electrochemical cell devices,15–17 plasmonic resonance platform,18–20 optical nanosensors,21–23 and chemiresistor.24 These analytic tools showed sensitive and rapid detection performances based on simple sensor signal readout without complex sample processing and specialized equipment. However, all of these methods are based on specific and complex surface chemistry design of substrate and transducers using subunit protein antibody and protein receptor such as DNA/RNA aptamers and angiotensin-converting enzyme 2 (ACE2) to selectively capture the SARS-CoV-2 viral proteins.25–27 These antibody or protein receptor functionalizations are expensive, fragile, prone to loss of biological activity with external treatment such as immobilization and device interfacing, and exhibit significant batch-dependent variations.28,29 In addition, they involve multiple processing step of fabrications including incubation, protein synthesis, and washing steps that require a significant amount of time to perform, limiting their use in widespread applications.30
Herein, we address this challenge using corona phase molecular recognition (CoPhMoRe) that enables the molecular recognition of SARS-CoV-2 viral proteins without the need for antibody or enzymatic receptor incorporation. Our recognition motif consists of specifically selected polyethylene glycol (PEG) - phospholipid heteropolymers adsorbed onto and structured by an underlying single-walled carbon nanotube (SWCNT), whereby a unique three-dimensional (3D) nanoparticle interface recognized nucleocapsid (N) and spike (S) protein of SARS-CoV-2 virus, resulting in rapid and label-free modulation of SWCNT near infrared (nIR) fluorescence. The presence of the N and S protein of SARS-CoV-2 elicits a robust and rapid nanosensor fluorescence changes up to 50% and 40% within 5 min analyte injections, and LOD were measured to be 48 fM and 350 pM, respectively. We also characterize the nanosensor stability in 100% human saliva condition and demonstrate that N protein sensing ability is completely preserved. Finally, on-site diagnosis system is demonstrated with a fiber optic (optode) benchtop platform that interfaces the advantages of antibody-free molecular recognition virus sensors on a 3D sensing tip.
RESULTS AND DISCUSSION
SWCNT synthesized by the high-pressure carbon monoxide (HiPCO) process were suspended with a specifically designed library of 11 PEG-phospholipid polymers capable of forming corona phases at the SWCNT surface (Figure 1a). PEG-phospholipid polymers are chosen for corona formation since previous studies have shown that PEG-phospholipid wrapped SWCNT were capable of detecting proteins in complex biofluid condition.31 In addition, chain length of PEG can be easily tuned to form wide range of the binding pocket, and they are commercially available thus, the preparation of polymer library is not time consuming. The accessible surface area of the PEG-phospholipid wrapped SWCNT was measured by titration using a quenchable fluorescent riboflavin probe following a recently developed molecular probe adsorption (MPA) technique (detailed procedure in Supplementary Note 1).32 Results show that DSPE-PEG5000 Amine formed the largest surface covering corona on SWCNT, and 16:0 PEG1000 PE formed smallest surface coverage corona (Figure 1b). The resulting colloidal solutions of nanosensors are characterized by ultraviolet-visible-nIR (UV-vis-nIR) absorption spectroscopy. Figure 1c shows the UV-vis-nIR absorption spectrum for the PEG-phospholipid corona phase, where the distinct and sharp peaks of E11 and E22 transitions indicate the successful isolation and suspension of individual SWCNT. nIR fluorescent emission spectra (Figure 1d) under 785 nm laser excitation demonstrate that nanosensors are mainly composed of (6, 5), (7, 6), and (9, 4) nanotube chirality.
Figure 1.
SARS-CoV-2 protein nanosensor library. (a) PEG-phospholipid library for CoPhMoRe based SWCNT nanosensors. (b) Accessible surface area of the PEG-phospholipid wrapped SWCNTs, where is the vacant binding site on SWCNT, and is the dissociation constant of probe binding to SWCNT. Assuming equivalent probe binding strength , a higher value represents more accessible surface area and less corona phase coverage. (c) UV-vis-nIR absorption spectrum of PEG-phospholipid/SWCNT nanosensor library with distinct and transitions. (d) nIR fluorescence spectrum of PEG-phospholipid/SWCNT nanosensor library under 785 nm excitation.
The nIR fluorescence response of PEG-phospholipid/SWCNT nanosensors was measured during SARS-CoV-2 N and S protein addition, schematically represented in Figure 2a. The N and S proteins can be recognized by specific 3D corona phase configurations of the PEG-phospholipid polymers imposed by the nanoparticle interfaces enabling rapid modulation of underlying nIR fluorescence intensity of the nanotube.31,33 In this way, the corona phase (PEG-phospholipid) acts as the receptor coupled directly to the fluorescent nanotube, which acts as the nonselective transducer. Note that specific recognition between the PEG and phospholipid independently of the nanotube surface is not expected. The combined polymer/nanotube construct is labeled CoPhMoRe. The unit composition of the polymers were varied to produce structurally diverse corona phases to sample a range of free-volumes and chemical interactions with the analyte influencing the dynamic binding/unbinding of viral proteins.34 In total, we explored 44 unique corona phases in this work based on 11 PEG-phospholipid polymer backbones. The responses of the resulting fluorescent emission of this library were recorded following a one hour incubation with each of viral protein target at 10 μg/mL in distinct buffer conditions. An identical concentration of strongly adsorbing bovine serum albumin (BSA) was used as an interferent to address both issues of non-specific binding and the stability of the sensor. Resulting bar graph chart of molecular binding shows distinct fluorescence responses with varying polymer compositions (Figure 2b). Here, and represent the integrated nIR intensity of nanosensors at and after viral proteins injection, respectively. Each nanosensor shows a unique turn-on or turn-off response to N proteins, S proteins, and BSA with response intensity changes from −70% to 212%. Most of the sensors demonstrate quenching or turnoff responses to N protein and intensity gains or turn-on responses to S protein. The 18:0 PEG1000 PE/SWCNT (hence-forth labeled nanosensor ii) and 14:0 PEG2000 PE/SWCNT (nanosensor vi) show the most obvious and clearly distinguishable responses to N protein and S protein respectively with strong 50 to 70% decreases in fluorescence intensity. Importantly, BSA appears to induce almost no response for these corona phase complexes. Thus, for the purposes of this work, nanosensor ii and nanosensor vi can be considered specific sensors for N protein and S protein, respectively. Fluorescent emission spectra demonstrate that nanosensor ii and nanosensor vi show significant nIR intensity decreases only to their specific protein targets (Figure S2a). Time-series emission spectra show that intensities of both nanosensors do not change after 60 min of buffer incubation, however, drastically change within 5 min of the addition of viral proteins (Figure S2b). More specifically, the normalized change in fluorescence of the 1125 nm emission peak corresponding to (7, 6) chirality SWCNT instantaneously decreased by 57% and 45% within 5 min (Figure S3), for nanosensor ii and nanosensor vi, respectively. The fluorescent response of nanosensor ii to N protein maintained for 60 min and response of nanosensor vi decrease after first peak response of S protein.
Figure 2.
SARS-CoV-2 protein nanosensor characterizations. (a) Schematics of CoPhMoRe mechanism of PEG-phospholipid/SWCNT nanosensors on N and S viral proteins. (b) Screening results of the integrated normalized response of nanosensors library on N protein (top) and S protein (bottom). Dashed lines indicate best nanosensor for each protein. The SWCNT and protein concentration (N protein, S protein, BSA) were 0.5 mg/L and 10 μg/mL, respectively. N protein buffer: 15 mM Na2HPO4, 5 mM NaH2PO4, 0.25 M NaCl, pH 7.5, S protein buffer: 2 mM Tris, 200 mM NaCl, pH 8.0. Data are mean (bar) ± (error bar), with replicates.
Real-time nIR sensor responses were measured using a wide range of concentrations from the fM to nM level of N and S proteins (Figure 3). Upon N and S protein addition, nanosensor ii (Figure 3a) and nanosensor vi (Figure 3b) show an instantaneous and continuous decrease in nIR signal on the order of 5 to 70% depending on protein concentrations. Nanosensor kinetic parameters were determined by fitting the maximum sensors response for 60 min to each analyte concentration series using the cooperative binding model of the Hill equation.35 For a first-order reversible reaction, the relationship between the analyte (A) and available docking sites (θ) for viral proteins can be described as follows:
| (1) |
Where Aθ the surface concentration of analyte bound sensor sites. The resulting equilibrium for this reaction is:
| (2) |
Figure 3.
The Limit of Detection (LOD) characterization of two SARS-CoV-2 protein nanosensors for N and S. Fluorescent emission spectra of (a) nanosensor ii and (b) nanosensor vi on wide concentration range (102 fg/mL to 1010 fg/mL) of N and S protein, respectively. Integrated fluorescence intensity at reaction time = 60 min for (c) nanosensor ii and (d) nanosensor vi with cooperative binding model fitting to quantify nanosensor kinetic parameters. Fitting parameters are and 0.683±0.092, and −0.005±0.009, and 0.213±0.071 nM, and and 1.120±0.197 for N and S protein, respectively. Data are mean (circle) ± σ (error bar), with replicates .
Assuming that the sensor response is proportional to the ratio, it is found that
| (3) |
with the total concentration of available recognition sites on the sensor a constant of and the parameter n for the analyte cooperativity. Fitting the data in Figure 3a–3b with equation (3) (R2 = 0.998 and 0.980) results in a proportionality factor and 0.683 with and −0.005, and 0.213 nM, and and 1.120 for N and S protein respectively, indicating positive cooperativity in good agreement with previous work (Figure 3c–3d).19 The Kd value of N and S protein nanosensors are lower than previously reported CoPhMoRe sensing which suggests influence of the larger molecular size of viral proteins, with more binding sites involved, and hence polyvalent interactions. The limit of detection in this mode is 49 fM and 350 pM for N and S protein respectively; this value was calculated by adding the nanosensor response from the addition of only buffer as the noise level to 3-times of the signal.
Our SARS-CoV-2 nanosensor compatibility in biofluids was assessed by testing the response to viral proteins in 1% and 100% human saliva (details in Table S1). For the N protein nanosensor, small sensor responses with 3.5 and 6.3% intensity change were observed with 1% and 100% saliva, respectively (left, Figure 4a). However, significantly larger responses to N protein in 100% saliva were observed with 45.4% change demonstrating that N protein detection appears to be independent of background saliva effects. SARS-CoV-2 patients show N protein concentration range from 10 to 104 pg/mL in their saliva during symptom of day 1 to 7.36 Since detecting range of our nanosensor vi (LOD of 2.4 pg/mL) sufficiently covers this clinical range, we expect that the CoPhMoRe nanosensor can diagnose the positive cases with real saliva sample. For the S protein nanosensor, on the other hand, the sensor responses to the analyte were clearly diminished in saliva conditions with almost similar changes for the control -S protein saliva and +S protein saliva samples (right, Figure 4a). The attenuation of the highly glycosylated S protein nanosensor response seems to arise from the decreased baseline of the fluorescence with saliva background.37,38 One hypothesis for future exploration is that the salivary glycoprotein can adsorb onto the S protein nanosensor surface and reduce the baseline fluorescence intensity and block viral protein binding. The N protein, on the other hand, is phosphorylated and the analyte-nanosensor interaction is not affected by glycoproteins present in saliva.39 The nIR fluorescence spectra demonstrate that our N protein nanosensor shows almost identical responses in buffer and the 100% human saliva condition (Figure 4b). This suggests that the PEG-phospholipid nanosensor passivation, built into this construct, enables at least partial reduction of nanosensor biofouling.21
Figure 4.
A Lab-on-Fiber on-site monitoring system of SARS-CoV-2 proteins based on nanosensor development in this work. (a) Normalized sensor responses of (left) nanosensor ii and (right) nanosensor vi to N and S proteins in buffer, saliva 1%, and saliva 100%. The SWCNT and protein concentration were 0.5 mg/L and 10 μg/mL, respectively. The data represent the mean value of replicates. (c) Photo-images of the fully-integrated fiber optic benchtop instrument with benchtop mobile cart. Sensor response to viral protein dropping were real-time measured under 561 nm laser excitation. (d) Real-time fiber optic monitoring of SARS-CoV-2 viral protein using CoPhMoRe nanosensor (10 μg/mL N protein, 5 μL droplet). Top: protein in buffer solution. Bottom: protein in saliva 100%.
In order to demonstrate a form of the sensor compatible with diagnosis in a non-laboratory setting, we interfaced the nanosensors in this work into a Lab-on-Fiber system using a fiber optic-based benchtop instrument to produce sensor optode. All components including the optode fiber, laser, nanosensors, nIR detectors, monitor, controller and test solutions can be compactly integrated onto a mobile cart, for example (left, Figure 4c). The optode fiber is flexible, lightweight, and robust enough such that the tip can be applied to samples for diagnosis with an ease not found with conventional analytical tools.40 We designed and fabricated 3D miniaturized sensor tips as interfaces that hold the SARS-CoV-2 nanosensor media and viral protein components stably onto the fiber optics using 3D-printing and a developed template (Objet 30 Prime, Stratasys Ltd). The sensing tip is engineered at high-resolution (mm-scale) in a specific 3D architecture such that viral proteins can be sensitively detected even with low volumes of biofluid extraction (currently < 10 μL). The printed 3D sensing tip was successfully integrated with the optode fiber by screwing onto an SMA (Sub-Miniature version A) connector and supported by an 8 mm-cover glass slide for the Lab-on-Fiber SARS-CoV-2 diagnosis system (left, Figure 4c). Figure 4d shows the real-time fluorescence response of the completed, fully-integrated optode fiber to SARS-CoV-2 N protein in buffer (top graph) and in 100% human saliva condition (bottom graph). A 5 μL viral protein solution was directly dropped onto the 3D printed sensing tip of the optode fiber and the resulting sensor response was directly measured using the benchtop instrument. The optode fiber itself generates no response to pure buffer spiked with BSA, but the expected rapid and sizable turn-off response to N protein in buffer with a 71.3% change in intensity. For the 100% saliva condition, the optode fiber appears to show a background quenching response to pure saliva (labeled -SARS-CoV-2) with a 30% change, the origins of which are unclear at this time. However, saliva plus analyte (labeled +SARS-CoV-2) demonstrates a response of 85.7%, easily above the background and statistically significant. A response time (τ90) of 5.1 min was achieved based on the time to reach 90% of the nIR level at infinity. Overall, the platform appears rapid enough for SARS-CoV-2 detection with small biofluid volume additions and short response time such that non-laboratory operation is possible.
We are also interested in the development timeline and workflow necessary to generate a sensor for virial detection starting from identification of the new virial target itself to deployable hardware ready for screening of the population. The CoPhMoRe technique seems to allow for rapid development, with libraries that can be screened at an accelerated pace to find a sensor optimum for a given viral target. Figure 5a shows the development timeline for this work following the experimental history of the project. We synthesized the whole CoPhMoRe library, performed characterization of the corona phases, screened against viral biomarkers and evaluated sensor performance for nanosensors for N and separately S protein targets within just 6 days of two researchers working 4 hours per day.
Figure 5.
Potential workflow for CoPhMoRe-based virial detection for a hypothetical future pandemic. (a) To estimate the labor scheduling for such a workflow, the timeline for the SARS-CoV-2 protein sensor development of this work is presented. Approximately 10 days of laboratory effort from two reseachers with approximately 4 hours per day completed the development. This includes experiments with associated waiting and analysis time, excluding reagent delivery time. (b) Schematic of an accelerated point-of-care sensor development with continual feedback to address emerging viral targets in the future.
In addition, these optimized nanosensor candidates could be efficiently integrated into a modular optode fiber optic setup and tested against the relevant biofluid (saliva) within 4 days. This sensor development depends on the design and selection of proper corona phase. Thus, in cases where no commercial polymer or chemistry show satisfying sensitivity and/or selectivity towards the target analytes, the development timeline may be extended. We argue that it is a unique feature of this type of molecular recognition scheme that rapid design and testing is possible, unhindered by the development time and supply chain requirements of a conventional antibody or enzymatic receptor. CoPhMoRe is also compatible with fully-automated fluorescence screening hardware that connects seamlessly to a benchtop optics platform. This rapid development workflow holds several potential advantages for future virial targets. Based on this, we expect that our CoPhMoRe platform can be readily applied to potential future pandemic with unknown viruses (Figure 5b). If a new virus target begins to circulate, this workflow can generate a corona interface library and synthesize recognition candidates within a few days. Computational analysis can be used to predict selectivity and sensitivity performance in advance of experimental validation. Then, the optimized nanosensor with selective recognition for the unknown virial target can be interfaced directly to the existing bench top platform shown in Figure 4c. Thus, the sensor produced from the CoPhMoRe-based sensor screening platform is potentially ready for field-deployment in advance of a future pandemic. In addition, based on the sensing and diagnosis data, we can also construct the database of CoPhMoRe sensor library onto a variety of viruses. In this way, the workflow allows for a potential feedback loop for continual sensor development targeting new, emerging viruses leveraging numerical modeling.
CONCLUSIONS
In summary, we have developed complexes of fluorescent SWCNT suspended using PEGylated lipid heteropolymers that selectively recognizes the N and S protein of SARS-CoV-2 virus. These synthetic, non-biological recognition sites provide an alternative for conventional SARS-CoV-2 detection methods, which suffer from major drawbacks including the need of special equipment and trained personnel, complex sample processing, long process time, and poor stability. In contrast, the SWCNT based nanosensors developed in this work apparently overcome these limitations by demonstrating stable and reproducible constructs that enable rapid and antibody-free detection of SARS-CoV-2 viral proteins with high sensitivity. Furthermore, the N protein sensor is shown to maintain functionality even in 100% human saliva. Future work will focus on incorporating the nanosensors into systems amenable to pointof-care applications, enabling rapid and label-free detection of the SARS-CoV-2 virus and its biomarkers. Our work also paves the way for the rapid development of the synthetic molecular recognition necessary for virial protein sensor development of future targets.
EXPERIMENTAL SECTION
Materials.
Raw single walled carbon nanotube (SWCNT) produced by HiPCO process were purchased from NanoIntegris and used without further processing (Batch# HR27–104). PEG-phospholipids were purchased from Avanti Polar Lipids Inc. All other chemicals were purchased from Sigma Millipore.
Nanosensor synthesis and characterizations.
In 1 mL of DI water, 1 mg (1 equiv.) HiPCO SWCNT and 1 mg (1 equiv.) of PEG-phospholipid were mixed. The mixture was ultrasonicated using a 1/8” probe (Cole-Parmer) at a power of 10 W for 30 minutes (QSonica). The resulting suspension was bench-top centrifuged twice at 30300 RCF for 1 hr (Eppendorf Centrifuge 5430R). The top 80% of the suspension was reserved for further use, while the remaining 20% was discarded. UV-vis-nIR absorption spectroscopy (Agilent Technologies, Cary 5000) was used to confirm successful suspensions and obtain the mass concentration of the nanoparticles using an extinction coefficient of mg.L−1.cm−1.41 The accessible surface area of the PEG-phospholipid wrapped SWCNT was measured using the molecular probe adsorption technique.32 Fluorescent emission (510 to 560 nm) intensity of riboflavin from to were measurement using a Thermo VarioSkan Plate, with excitation at 460 nm. Deflections of the riboflavin fluorescence were taken in the presence of nanosensor suspensions with SWCNT concentration of 10 mg/L.
nIR signal measurements.
High throughput screening of the nanosensor library against the viral proteins was performed using a customized nIR microscope, which consists of a Zeiss Axio Vision inverted microscope body with a 20X objective, coupled to an Acton SP2500 spectrometer and liquid nitrogen cooled InGaAs 1D detector (Princeton Instruments). In a 96-well plate, one PEG-phospholipid/SWCNT sensor (0.5 mg/L) and one viral protein (N or S protein, 10 μg/mL) were mixed in a final volume of 200 μL in N protein buffer (15 mM Na2HPO4, 5 mM NaH2PO4, 0.25 M NaCl, pH 7.5) and S protein buffer (2 mM Tris, 200 mM NaCl, pH 8.0), and incubated for 1 hr in each well. The samples were then illuminated by a 150 mW 785 nm photodiode laser (B&W Tek Inc.), and fluorescence emission spectra were collected from 950 to 1250 nm. Peak position and intensities of each sensor–viral proteins pair were compared to a nanosensor/buffer and nanosensor/BSA control to calculate the selective sensor responses. The most promising candidates were identified and studied further. Proteins and saliva were sourced and reconstituted as listed in Table S1. 1% and 100% saliva are calculated from the saliva concentration of whole analyte solution including viral proteins.
Optode fiber measurements.
Sensors were excited with 561 nm (MGL-FN-561 200mW, Opto Engine LLC) or 785 nm (MDL-III-785 500mW, Opto Engine LLC). The laser light propagates through fiber optic reflection/backscatter probe bundles (RP29, Thorlabs) to the samples, and the fluorescence light propagates through the fiber to InGaAs amplified photodetector (PDF10C, Thorlabs). The fiber optic probe consists of 6 fibers around 1 fiber configuration where the central fiber provides the light delivery to the PEG-phospholipid/SWCNT nanosensor. The surrounding 6 fibers collect the near infrared fluorescence light from nanosensor. To reduce laser scattering and autofluorescence at hydrogel, 900 nm short pass filter and 900 nm long pass filter were inserted at the laser and photodetector, respectively. A focusing lens with a focal length of 30 mm is placed to efficiently collect fluorescence signal at 0.5 mm-diameter active area of the photodetector. All the components of the instrument are loaded on a mobile cart (15Y320, Grainger, size: depth 18”, width 24”, height 26–42”). For the real-time signal measurement of SARS-CoV-2, 5 μL buffer, BSA (10 μg/mL), and N protein (10 μg/mL) were added in series and fluorescence signals were measured for 30 min. 3D sensing tips were fabricated using a 3D printer (Objet 30 Prime, Stratasys Ltd.). The print was executed using “High Quality” settings and VeroClear (PN: OBJ-04055, Stratasys) material with a minimum layer thickness of 16 μm. The prints were washed from the support material using an electric power washer (supplied by Stratasys). Resolution of 3D printer is X-axis: 600 dpi; Y-axis: 600 dpi; Z-axis: 1600 dpi and accuracy is 0.1 mm (0.0039”).
Supplementary Material
ACKNOWLEDGMENT
The authors are grateful for helpful discussions with Dr. Roya Khosravi-Far, InnoTech Precision Medicine, Inc. SPIKE (Stable) protein was a generous gift from Dr. Jason McLellan (Department of Molecular Biosciences, University of Texas, Austin, TX 78712, USA). Financial support for this work was from the National Institute of Health (NIH) Rapid Acceleration of Diagnostics (RADX) 1R42DE030829 to Dr. Roya Khosravi-Far.
Footnotes
ASSOCIATED CONTENT
Supporting Information
Nanotube surface coverage characterization, molecular probe adsorption curve with slope inversely proportional to the accessible surface area, fluorescent emission spectra of nanosensor ii and nanosensor vi on control buffer, BSA, and viral protein, fluorescent emission spectra variation of nanosensors as a function of time, and proteins and saliva specifications used for the study. The Supporting Information is available free of charge on the ACS Publications website.
The authors declare no competing interest. The raw data presented in this manuscript are publicly available on the dbGaP website. https://www.ncbi.nlm.nih.gov/projects/gapprev/gap/cgi-bin/study.cgi?study_id=phs002574.v1.p1
REFERENCES
- (1).Kronbichler A; Kresse D; Yoon S; Lee KH; Effenberger M; Shin JI Asymptomatic Patients as a Source of COVID-19 Infections: A Systematic Review and Meta-Analysis. Int. J. Infect. Dis. 2020, 98, 180–186. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (2).Udugama B; Kadhiresan P; Kozlowski HN; Malekjahani A; Osborne M; Li VYC; Chen H; Mubareka S; Gubbay JB; Chan WCW Diagnosing COVID-19: The Disease and Tools for Detection. ACS Nano 2020, 14, 38223835. [DOI] [PubMed] [Google Scholar]
- (3).Pokhrel P; Hu C; Mao H. Detecting the Coronavirus (COVID-19). ACS Sens. 2020, 5, 2283–2296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (4).Esbin MN; Whitney ON; Chong S; Maurer A; Darzacq X; Tjian R. Overcoming the Bottleneck to Widespread Testing: A Rapid Review of Nucleic Acid Testing Approaches for COVID-19 Detection. RNA 2020, 26, 771–783. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (5).Mio C; Cifù A; Marzinotto S; Bergamin N; Caldana C; Cattarossi S; Cmet S; Cussigh A; Martinella R; Zucco J; Verardo R; Schneider C; Marcon B; Zampieri S; Pipan C; Curcio F. A Streamlined Approach to Rapidly Detect SARS-CoV-2 Infection Avoiding RNA Extraction: Workflow Validation. Dis. Markers 2020, 2020, 8869424. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (6).McMinn S; Carlsen A; Jaspers B; Talbot R; Adeline S. In Large Texas Cities, Access To Coronavirus Testing May Depend On Where You Live. https://www.npr.org/sections/health-shots/2020/05/27/862215848/across-texas-blackand-hispanic-neighborhoods-havefewer-coronavirus-testing-sit (accessed June 17, 2021).
- (7).Kim S; Hao Y; Miller EA; Tay DMY; Yee E; Kongsuphol P; Jia H; McBee M; Preiser PR.; Sikes HD Vertical Flow Cellulose-Based Assays for SARS-CoV-2 Antibody Detection in Human Serum. ACS Sens. 2021, 6, 1891–1898. [DOI] [PubMed] [Google Scholar]
- (8).EUA Authorized Serology Test Performance. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance (Accessed on June 17, 2021).
- (9).Whitman JD; Hiatt J; Mowery CT; Shy BR; Yu R; Yamamoto TN; Rathore U; Goldgof GM; Whitty C; Woo JM; Gallman AE; Miller TE; Levine AG; Nguyen DN; Bapat SP; Balcerek J; Bylsma SA; Lyons AM; Li S; Wong AW; Gillis-Buck EM; Steinhart ZB; Lee Y; Apathy R; Lipke MJ; Smith JA; Zheng T; Boothby IC; Isaza E; Chan J; Acenas DD II; Lee J; Macrae TA; Kyaw TS; Wu D; Ng DL; Gu W; York VA; Eskandarian HA; Callaway PC; Warrier L; Moreno ME; Levan J; Torres L; Farrington LA; Loudermilk R; Koshal K; Zorn KC; Garcia-Beltran WF; Yang D; Astudillo MG; Bernstein BE; Gelfand JA; Ryan ET; Charles RC; Iafrate AJ; Lennerz JK; Miller S; Chiu CY; Stramer SL; Wilson MR; Manglik A; Ye CJ; Krogan NJ; Anderson MS; Cyster JG; Ernst JD; Wu AHB; Lynch KL; Bern C; Hsu PD; Marson A. Test Performance Evaluation of SARS-CoV-2 Serological Assays. medRxiv Preprint 2020, DOI: 10.1101/2020.04.25.20074856. [DOI] [Google Scholar]
- (10).Vandenberg O; Martiny D; Rochas O; van Belkum A; Kozlakidis Z. Considerations for Diagnostic COVID-19 Tests. Nat. Rev. Microbiol. 2021, 19, 171–183. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (11).American Society for Microbiology. Laboratory Supply Shortages Are Impacting COVID-19 and Non-COVID Diagnostic Testing. https://asm.org/Articles/2020/September/Laboratory-Supply-Shortages-Are-Impacting-COVID-19 (accessed on June 18, 2021).
- (12).Seo G; Lee G; Kim MJ; Baek S-H; Choi M; Ku KB; Lee C-S; Jun S; Park D; Kim HG; Kim S-J; Lee J-O; Kim BT; Park EC; Kim SI Rapid Detection of COVID-19 Causative Virus (SARS-CoV-2) in Human Nasopharyngeal Swab Specimens Using Field-Effect TransistorBased Biosensor. ACS Nano 2020, 14, 5135–5142. [DOI] [PubMed] [Google Scholar]
- (13).Shao W; Shurin MR; Wheeler SE; He X; Star A. Rapid Detection of SARS-CoV-2 Antigens Using High-Purity Semiconducting Single-Walled Carbon Nanotube-Based FieldEffect Transistors. ACS Appl. Mater. Interfaces 2021, 13, 10321–10327. [DOI] [PubMed] [Google Scholar]
- (14).Zhang X; Qi Q; Jing Q; Ao S; Zhang Z; Ding M; Wu M; Liu K; Wang W; Ling Y; Zhang Z; Fu W. ElecTrical Probing of COVID-19 Spike Protein Receptor Binding Domain via A Graphene Field-Effect Transistor. arXiv:2003.12529; https://arxiv.org/abs/2003.12529 (accessed June 17, 2021). [Google Scholar]
- (15).Guo K; Wustoni S; Koklu A; Díaz-Galicia E; Moser M; Hama A; Alqahtani AA; Ahmad AN; Alhamlan FS; Shuaib M; Pain A; McCulloch I; Arold ST; Grünberg R; Inal S. Rapid Single-Molecule Detection of COVID-19 and MERS Antigens via Nanobody-Functionalized Organic Electrochemical Transistors. Nat. Biomed. Eng. 2021, 10.1038/s41551-021-00734-9. [DOI] [PubMed] [Google Scholar]
- (16).Mahari S; Roberts A; Shahdeo D; Gandhi S. eCov-Sens-Ultrasensitive Novel In-House Built Printed Circuit Board Based Electrochemical Device for Rapid Detection of nCovid-19 antigen, a spike protein domain 1 of SARS-CoV-2. bioRxiv Preprint 2020, DOI: 10.1101/2020.04.24.059204. [DOI] [Google Scholar]
- (17).Beduk T; Beduk D; Filho JIDO; Zihnioglu F; Cicek C; Sertoz R; Arda B; Goksel T; Turhan K; Salama KN; Timur S. Rapid Point-of-Care COVID-19 Diagnosis with a Gold-Nanoarchitecture-Assisted Laser-Scribed Graphene Biosensor. Anal. Chem. 2021, 93, 8585–8594. [DOI] [PubMed] [Google Scholar]
- (18).Qiu G; Gai Z; Tao Y; Schmitt J; Kullak-Ublick GA; Wang J. Dual-Functional Plasmonic Photothermal Biosensors for Highly Accurate Severe Acute Respiratory Syndrome Coronavirus 2 Detection. ACS Nano 2020, 14, 5268–5277. [DOI] [PubMed] [Google Scholar]
- (19).Ahmadivand A; Gerislioglu B; Ramezani Z; Kaushik A; Manickam P; Ghoreishi SA Functionalized Terahertz Plasmonic Metasensors: Femtomolar-Level Detection of SARS-CoV-2 Spike Proteins. Biosens. Bioelectron. 2021, 177, 112971. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (20).Chen H; Park S-G; Choi N; Kwon H-J; Kang T; Lee M-K Choo J. Sensitive Detection of SARS-CoV-2 Using a SERS-Based Aptasensor. ACS Sens. 2021, 6, 2378–2385. [DOI] [PubMed] [Google Scholar]
- (21).Pinals RL; Ledesma F; Yang D; Navarro N; Jeong S; Pak JE; Kuo L; Chuang Y-C; Cheng Y-W; Sun H-Y; Landry MP Rapid SARS-CoV-2 Spike Protein Detection by Carbon Nanotube-Based Near-Infrared Nanosensors. Nano Lett. 2021, 21, 2272–2280. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (22).Chen R; Ren C; Liu M; Ge X; Qu M; Zhou X; Liang M; Liu Y; Li F. Early Detection of SARS-CoV-2 Seroconversion in Humans with Aggregation-Induced Near-Infrared Emission Nanoparticle-Labeled Lateral Flow Immunoassay. ACS Nano 2021, 15, 8996–9004. [DOI] [PubMed] [Google Scholar]
- (23).Moitra P; Alafeef M; Dighe K; Frieman MB.; Pan D. Selective Naked-Eye Detection of SARS-CoV-2 Mediated by N Gene Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles. ACS Nano 2020, 14, 7617–7627. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (24).Shan B; Broza YY; Li W; Wang Y; Wu S; Liu Z; Wang J; Gui S; Wang L; Zhang Z; Liu W; Zhou S; Jin W; Zhang Q; Hu D; Lin L; Zhang Q; Li W; Wang J; Liu H; Pan Y; Haick H. Multiplexed Nanomaterial-Based Sensor Array for Detection of COVID-19 in Exhaled Breath. ACS Nano 2020, 14, 12125–12132. [DOI] [PubMed] [Google Scholar]
- (25).Du L; He Y; Zhou Y; Liu S; Zheng B-J; Jiang S. The Spike Protein of SARS-CoV - a Target for Vaccine and Therapeutic Development. Nat. Rev. Microbiol. 2009, 7, 226–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (26).Lan J; Ge J; Yu J; Shan S; Zhou H; Fan S; Zhang Q; Shi X; Wang Q; Zhang L; Wang X. Structure of the SARS-CoV-2 Spike Receptor-Binding Domain Bound to the ACE2 Receptor. Nature 2020, 581, 215–220. [DOI] [PubMed] [Google Scholar]
- (27).Jia H; Zhang A; Yang Y; Cui Y; Xu J; Jiang H; Tao S; Zhang D; Zeng H; Hou Z; Feng J. A graphene oxide coated tapered microfiber acting as a super-sensor for rapid detection of SARS-CoV-2. Lab Chip. 2021, 21, 2398–2406. [DOI] [PubMed] [Google Scholar]
- (28).Saerens D; Huang L; Bonroy K; Muyldermans S. Antibody Fragments as Probe in Biosensor Development. Sensors 2008, 8, 4669–4686. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (29).Peluso P; Wilson DS; Do D; Tran H; Venkatasubbaiah M; Quincy D; Heidecker B; Poindexter K; Tolani N; Phelan M; Witte K; Jung LS; Wagner P; Nock S. Optimizing Antibody Immobilization Strategies for the Construction of Protein Microarrays. Anal. Biochem. 2003, 312, 113–124. [DOI] [PubMed] [Google Scholar]
- (30).Charter NW; Horecka J; Loh CY; Doan A; Wehrman T; Olson KR Rapid, Antibody-Free Detection of Recombinant Proteins on Blots Using Enzyme Fragment Complementation. Methods Mol. Biol. 2009, 536, 395–405. [DOI] [PubMed] [Google Scholar]
- (31).Bisker G; Dong J; Park HD; Iverson NM; Ahn J; Nelson JT; Landry MP; Kruss S; Strano MS ProteinTargeted Corona Phase Molecular Recognition. Nat. Commun. 2016, 7, 10241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (32).Park M; Salem DP; Parviz D; Gong X; Silmore KS; Lew TTS; Khong DT; Ang MC-Y; Kwak SY; Chan-Park MB; Strano MS Measuring the Accessible Surface Area within the Nanoparticle Corona Using Molecular Probe Adsorption. Nano Lett. 2019, 19, 7712–7724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (33).Zhang JQ; Landry MP; Barone PW; Kim JH; Lin SC; Ulissi ZW; Lin DH; Mu B; Boghossian AA; Hilmer AJ; Rwei A; Hinckley AC; Kruss S; Shandell MA; Nair N; Blake S; Sen F; Sen S; Croy RG; Li D; Yum K; Ahn J-H; Jin H; Heller DA; Essigmann JM; Blankschtein D; Strano MS Molecular Recognition Using Corona Phase Complexes Made of Synthetic Polymers Adsorbed on Carbon Nanotubes. Nat. Nanotechnol. 2013, 8, 959–968. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (34).Lee MA; Wang S; Jin X; Bakh NA; Nguyen FT; Dong J; Silmore KS; Gong X; Pham C; Jones KK; Muthupalani S; Bisker G; Son M; Strano MS Implantable Nanosensors for Human Steroid Hormone Sensing In Vivo Using a Self-Templating Corona Phase Molecular Recognition. Adv. Healthcare Mater. 2020, 9, 2000429. [DOI] [PubMed] [Google Scholar]
- (35).Kruss S; Landry MP; Vander Ende E; Lima BMA; Reuel NF; Zhang J; Nelson J; Mu B; Hilmer A; Strano M. Neurotransmitter Detection Using Corona Phase Molecular Recognition on Fluorescent Single-Walled Carbon Nanotube Sensors. J. Am. Chem. Soc. 2014, 136, 713–724. [DOI] [PubMed] [Google Scholar]
- (36).Shan D; Johnson JM; Fernandes SC; Suib H; Hwang S; Wuelfing D; Mendes M; Holdridge M; Burke EM; Beauregard K; Zhang Y; Cleary M; Xu S; Yao X; Patel PP; Plavina T; Wilson DH; Chang L; Kaiser KM; Nattermann J; Schmidt SV; Latz E; Hrusovsky K; Mattoon D; Ball AJ N-Protein Presents Early in Blood, Dried Blood and Saliva During Asymptomatic and Symptomatic SARS-CoV-2 Infection. Nat. Commun. 2021, 12, 1931. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (37).Hernández ER; Hernández-Zimbrón LF; Zúñiga NM; Leal-García JJ; Hernández VI; Ucharima-Corona LE; Campos EP; Zenteno E. The Role of the SARS-CoV-2 S-Protein Glycosylation in the Interaction of SARS-CoV-2/ACE2 and Immunological Responses. Viral Immunol. 2021, 34, 165–173. [DOI] [PubMed] [Google Scholar]
- (38).Watanabe Y; Allen JD; Wrapp D; McLellan JS; Crispin M. Site-Specific Glycan Analysis of the SARS-CoV-2 Spike. Science 2020, 369, 330–333. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (39).Bouhaddou M; Memon D; Meyer B; White KM; Rezelj VV; Correa Marrero M; Polacco BJ; Melnyk JE; Ulferts S; Kaake RM; Batra J; Richards AL; Stevenson E; Gordon DE; Rojc A; Obernier K; Fabius JM; Soucheray M; Miorin L; Moreno E; Koh C; Tran QD; Hardy A; Robinot R; Vallet T; NilssonPayant BE; Hernandez-Armenta C; Dunham A; Weigang S; Knerr J; Modak M; Quintero D; Zhou Y; Dugourd A; Valdeolivas A; Patil T; Li Q; Hüttenhain R; Cakir M; Muralidharan M; Kim M; Jang G; Tutuncuoglu B; Hiatt J; Guo JZ; Xu J; Bouhaddou S; Mathy CJP; Gaulton A; Manners EJ; Felix E; Shi Y; Goff M; Lim JK; McBride T; O’Neal MC; Cai Y; Chang JCJ; Broadhurst DJ; Klippsten S; De Wit E; Leach AR; Kortemme T; Shoichet B; Ott M; SaezRodriguez J; tenOever BR; Mullins RD; Fischer ER; Kochs G; Grosse R; García-Sastre A; Vignuzzi M; Johnson JR; Shokat KM; Swaney DL; Beltrao P; Krogan NJ The Global Phosphorylation Landscape of SARS-CoV-2 Infection. Cell 2020, 182, 685–712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- (40).Kozawa D; Cho S-Y; Gong X; Nguyen FT; Jin X; Lee MA; Lee H; Zeng A; Xue G; Schacherl J; Gibson S; Vega L; Strano MS A Fiber Optic Interface Coupled to Nanosensors: Applications to Protein Aggregation and Organic Molecule Quantification. ACS Nano 2020, 14, 10141–10152. [DOI] [PubMed] [Google Scholar]
- (41).Zhang J; Kruss S; Hilmer AJ; Shimizu S; Schmois Z; Cruz FDL; Barone PW; Reuel NF; Heller DA; Strano MS A Rapid, Direct, Quantitative, and Label-Free Detector of Cardiac Biomarker Troponin T Using Near-Infrared Fluorescent Single-Walled Carbon Nanotube Sensors. Adv. Healthc. Mater. 2014, 3, 412–423. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.





